Kim Kook Hwan, Lee Myung-Shik
Severance Biomedical Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Front Endocrinol (Lausanne). 2018 Aug 24;9:485. doi: 10.3389/fendo.2018.00485. eCollection 2018.
Non-alcoholic fatty liver disease (NAFLD) is an emerging global health problem and a potential risk factor for type 2 diabetes, cardiovascular disease, and chronic kidney disease. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, is a predisposing factor for development of cirrhosis and hepatocellular carcinoma. The increasing prevalence of NASH emphasizes the need for novel therapeutic approaches. Although therapeutic drugs against NASH are not yet available, fundamental insights into the pathogenesis of NASH have been made during the past few decades. Multiple therapeutic strategies have been developed and are currently being explored in clinical trials or preclinical testing. The pathogenesis of NASH involves multiple intracellular/extracellular events in various cell types in the liver or crosstalk events between the liver and other organs. Here, we review current findings and knowledge regarding the pathogenesis of NASH, focusing on the most recent advances. We also highlight hormone-based therapeutic approaches for treatment of NASH.
非酒精性脂肪性肝病（NAFLD）是一个新出现的全球性健康问题，也是2型糖尿病、心血管疾病和慢性肾脏病的潜在危险因素。非酒精性脂肪性肝炎（NASH）是NAFLD的一种严重形式，是肝硬化和肝细胞癌发生的一个诱发因素。NASH患病率的不断上升凸显了新型治疗方法的必要性。尽管目前尚无针对NASH的治疗药物，但在过去几十年里，人们对NASH的发病机制有了基本认识。已经开发了多种治疗策略，目前正在临床试验或临床前测试中进行探索。NASH的发病机制涉及肝脏中各种细胞类型的多个细胞内/细胞外事件，或肝脏与其他器官之间的相互作用事件。在此，我们综述了有关NASH发病机制的当前研究结果和知识，重点关注最新进展。我们还强调了基于激素的NASH治疗方法。
